Diflunisal: a review of pharmacokinetic and pharmacodynamic properties, drug interactions, and special tolerability studies in humans.
Open Access
- 1 February 1977
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 4 (S1) , 31S-36S
- https://doi.org/10.1111/j.1365-2125.1977.tb04511.x
Abstract
1 In the fasting state, peak plasma levels of diflunisal were achieved within 2 hours. The drug was not metabolized and almost totally excreted in the urine as unchanged or conjugated drug. The terminal plasma half-life was approximately 8 hours. These results support a twice daily dose regimen.Keywords
This publication has 9 references indexed in Scilit:
- Physiological disposition and metabolism of 5-(2',4'-difluorophenyl)salicyclic acid, a new salicylate.1975
- Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides.Proceedings of the National Academy of Sciences, 1975
- Isolation and Structure of Two Prostaglandin Endoperoxides That Cause Platelet AggregationProceedings of the National Academy of Sciences, 1974
- Nonsteroid Anti-Inflammatory AgentsAnnual Review of Pharmacology, 1973
- Inhibition of prostaglandin synthesis in manBiochemical and Biophysical Research Communications, 1972
- Effects of large and small doses of hydrochlorothiazide in hypertensive patientsClinical Pharmacology & Therapeutics, 1970
- Salicylate OtotoxicityNew England Journal of Medicine, 1965
- STUDY OF THE PARADOXICAL EFFECTS OF SALICYLATE IN LOW, INTERMEDIATE AND HIGH DOSAGE ON THE RENAL MECHANISMS FOR EXCRETION OF URATE IN MAN *Journal of Clinical Investigation, 1959
- REAPPRAISAL OF THE HYPOGLYCEMIC ACTION OF ACETYLSALICYLATE1959